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The Role of Aspirin in Cardiovascular Prevention
Implications of Aspirin Resistance
Armen Yuri Gasparyan, MD, PHD, Timothy Watson, MRCP, Gregory Y. H. Lip, MD, FRCP
Birmingham, United Kingdom
Aspirin is well recognized as an effective antiplatelet drug for secondary prevention in subjects at high risk of
cardiovascular events. However, most patients receiving long-term aspirin therapy still remain at substantial risk
of thrombotic events due to insufficient inhibition of platelets, specifically via the thromboxane A2 pathway. Al-
though the exact prevalence is unknown, estimates suggest that between 5.5% and 60% of patients using this
drug may exhibit a degree of “aspirin resistance,” depending upon the definition used and parameters mea-
sured. To date, only a limited number of clinical studies have convincingly investigated the importance of aspirin
resistance. Of these, few are of a sufficient scale, well designed, and prospective, with aspirin used at standard
doses. Also, most studies do not sufficiently address the issue of noncompliance to aspirin as a frequent, yet
easily preventable cause of resistance to this antiplatelet drug. This review article provides a comprehensive
overview of aspirin resistance, discussing its definition, prevalence, diagnosis, and therapeutic approaches.
Moreover, the clinical implications of aspirin resistance are explored in various cardiovascular disease states,
including diabetes mellitus, hypertension, heart failure, and other similar disorders where platelet reactivity is
enhanced. (J Am Coll Cardiol 2008;51:1829–43) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.080e
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Whe fascinating history of aspirin-like remedies traces back
o antiquity. The Assyrians and the Egyptians were well
ware of the analgesic effects of a decoction of myrtle or
illow leaves for joint pain (1). Since the times of Hip-
ocrates, Celsus, Pliny the Elder, Dioscorides, and Galen,
emedies made from willow bark were used as antipyretic
nd antirheumatic therapies (2). In 1838, the Italian chem-
st, Rafaelle Piria discovered the active ingredient in willow
ark—salicylic acid (3). However, it was not until some 60
ears later when in 1897, Felix Hoffman, who worked for
he Bayer pharmaceutical company in Germany, synthe-
ized the acetylated form of salicylic acid, which was named
aspirin,” and became the most widely used drug of all time
4). Aspirin differed markedly from previous forms of
alicylic acid, with improved tolerability and reduced gas-
rointestinal side effects, and remains widely used as both an
nti-inflammatory and antirheumatic drug.
A new era of aspirin usage began in 1971 when Sir John
ane demonstrated that the main mechanism of action was
he inhibition of prostaglandin synthesis (5). The critical
mportance of this discovery was underlined in 1982 when
ane was awarded the Nobel Prize for Medicine (1).
ubsequent clinical and experimental studies have demon-
trated that low-dose aspirin irreversibly acetylates a serine
esidue at position 530 on the cyclooxygenase-1 (COX-1)
rom the Haemostasis Thrombosis and Vascular Biology Unit, University Depart-
ent of Medicine, City Hospital, Birmingham, United Kingdom.g
Manuscript received September 13, 2007; revised manuscript received October 19,
007, accepted November 10, 2007.nzyme in platelets, thus blocking synthesis of prostaglandin
2/H2 (Fig. 1). This reaction is the first in a series that
llows transformation of arachidonic acid into the potent
latelet agonist, thromboxane A2, thereby leading to the
eneficial clinical effect of aspirin in patients with coronary
rtery disease and stroke (6–9).
The importance of aspirin therapy in this setting is sealed
y a large meta-analysis from the Antithrombotic Trialists’
ollaboration (287 randomized trials of antiplatelet therapy
f patients at high risk of occlusive vascular events), which
emonstrated a 32% reduction of nonfatal myocardial in-
arction (MI), nonfatal stroke, and vascular death in patients
reated with 75 to 150 mg aspirin daily (10). Despite such
trong evidence, it is increasingly appreciated that some
atients still fail to respond adequately to aspirin therapy.
his is usually seen by the occurrence of further clinical
thrombotic) events despite aspirin treatment in “usual”
rophylactic dosages. Such “aspirin resistance” has also been
efined in the laboratory setting by the failure of aspirin to
ully inhibit platelet aggregation.
This review provides an overview on the importance of
spirin therapy in primary and secondary prevention of
ascular disease and explores the purported role of aspirin
esistance and the implications of this for everyday clinical
ractice.
earch Criteria
e performed a comprehensive search of electronic biblio-
raphic databases (e.g., MEDLINE, EMBASE, DARE)
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ing key words related to aspirin
use in randomized clinical trials.
In addition, several relevant full-
text review articles were identi-
fied from ProQuest Medical
Library. We hand searched bib-
liographies for important arti-
cles and reviewed abstracts from
major conferences. We also
searched the open databases of
the Cochrane Collaboration and
the Clinical Trials database for
other relevant studies.
spirin in the Prevention of Vascular Disease
he role of aspirin in primary prevention of vascular
isease has been investigated in 6 randomized controlled
rials (11–16) and in several meta-analyses (17,18), as
ummarized in Table 1. Although 4 of these trials clearly
ndicate the importance of aspirin for primary prevention
11,13–15), a meta-analysis of all trials (n  95,456
articipants, 54% women) for an average follow-up pe-
iod of 6.4 years surprisingly did not find a significant
eduction in the risk of stroke, cardiovascular, or all-cause
ortality (17,18), presumably because the majority of
atients included were, in fact, at low risk for vascular
isease.
Figure 1 Inhibition of Platelet Thromboxane A2
Pathways by Low-Dose Aspirin
Figure illustration by Rob Flewell.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ADP  adenosine
diphosphate
CI  confidence interval
COX  cyclooxygenase
CRP  C-reactive protein
MI  myocardial infarction
NO  nitric oxide
RPFA  rapid platelet
function assaytAmong the randomized trials, the Physicians’ Health
tudy (11) merits special attention. This prospective study
ot only demonstrated the important efficacy of aspirin in
educing vascular events, but also explored the link between
hronic inflammation and atherothrombosis. The investiga-
ors found that levels of C-reactive protein (CRP) (a marker
f inflammation) were predictive of future MI and stroke,
nd that the greatest and most statistically significant
eduction in risk of a first MI associated with aspirin use was
bserved among men with baseline CRP levels in the
ighest quartile.
In contrast to the conflicting data for primary prevention,
he majority of studies of aspirin for secondary prevention
ave clearly shown the positive efficacy of this drug. One
mportant example is the ISIS-2 (Second International
tudy of Infarct Survival) study, where the benefits of early
dministration of 162.5 mg of aspirin after acute MI were
lear. After 35 days follow-up from the index event, a 9.4%
eath rate was observed in the aspirin group compared with
2.0% in the placebo arm (risk ratio 0.78; 95% confidence
nterval [CI] 0.71 to 0.85; p  0.0001) (19).
The inequity in efficacy for aspirin between primary and
econdary prevention trials and the apparent failure of
spirin to suppress further events in some patients raises
mportant questions. 1) In which patient group(s) does
spirin therapy have the greatest efficacy? 2) Which factors
re implicated in aspirin treatment failure (aspirin resis-
ance)? 3) Are laboratory assays available to reliably identify
atients who will not sufficiently respond to aspirin? 4) Is
ombined antiplatelet therapy more advantageous than as-
irin alone?
Aspirin Resistance” and Its Implications
here has been a staggering increase in the volume of
iterature addressing the issue of so-called “aspirin resis-
ance” in recent years. Terminology and definitions vary
idely, some based on clinical observations and other
ased upon measurement of various laboratory parame-
ers, defined from both in vivo and in vitro studies.
The term “aspirin resistance” has various synonyms, includ-
ng “aspirin nonresponsiveness,” “aspirin treatment failure,”
nd “inadequate aspirin efficacy,” but has also been sometimes
efined as “biochemical or laboratory aspirin resistance”
20,21). Estimates of the prevalence of aspirin resistance vary
idely (5.5% to 60%), reflecting the diversity of various labora-
ory assays and confounding from the broad range of disease
tates investigated (22–27).
To the practicing clinician, a definition and diagnosis of
spirin resistance based on clinical assessment of treatment
utcomes (i.e., adverse vascular events) would seem prefer-
ble. Nevertheless, the major limitation to this approach is
hat it relies upon a retrospective review of clinical events.
or this reason, most researchers are increasingly advocatinghe application of various laboratory tests.
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ight or optical aggregometry, which is generally consid-
red the “gold standard” of platelet function assessment, is
he most widely used technique for defining aspirin resis-
ance. The technique is based on the increase in light
ransmission through platelet-rich plasma as a result of
ggregation of platelets and formation of clumps in response
o various agonists. Although numerous agonists (e.g.,
rachidonic acid, adenosine diphosphate [ADP], epineph-
ine, collagen, thrombin) can be used, the most specific for
etection of aspirin resistance appears to be arachidonic
andomized Controlled Trials on Aspirin in Primary Prevention of C
Table 1 Randomized Controlled Trials on Aspirin in Primary Pre
Study Study Design
Physician’s health study (11) 1,086 apparently healthy male
physicians, age 40 to 84 yrs, were
assigned to 325 mg of aspirin or
placebo on alternate days.
British doctors’ trial (12) A 6-yr randomized trial among 5,139
apparently healthy male physicians
taking 500 mg aspirin daily. End
point: incidence of and mortality
from stroke, MI, or other vascular
conditions.
Thrombosis prevention trial (13) 5,499 men age 45 to 69 yrs at high
risk of ischemic heart disease
assigned to warfarin plus aspirin 75
mg, warfarin plus placebo aspirin,
aspirin 75 mg plus placebo
warfarin, or placebo warfarin plus
placebo aspirin.
Primary end point was all IHD defined
as the sum of fatal and nonfatal
events (coronary death and fatal
and nonfatal MI).
Hypertension optimal treatment
trial (14)
9,399 patients with hypertension (both
men and women) were randomly
assigned to aspirin 75 mg daily and
9,391 patients to placebo. The trial
was designed to assess the
efficacy of adding aspirin to
antihypertensive therapy for primary
prevention. End points were major
CV events (nonfatal MI, nonfatal
stroke, and CV death).
Primary prevention project (15) 4,495 patients (mean age 64.4 yrs)
with at least 1 major CV risk factor
were randomly allocated to receive
1 tablet of 100 mg enteric-coated
aspirin daily or placebo.
Mean follow-up period was 3.6 yrs. The
end point was the cumulative rate
of CV death, nonfatal MI, and
nonfatal stroke.
Women’s health study (16) 39,876 healthy women age above 45
yrs randomized to receive 100 mg
aspirin on alternate days or placebo
and monitored for 10 years for a
first major CV event.
I  confidence interval; CRP  C-reactive protein; CV  cardiovascular; IHD  ischemic heart dicid, which induces platelet aggregation through the throm- aoxane A2 pathway. Using this method, the most widely
ccepted definition of aspirin resistance is 20% platelet
ggregation with 1 mg/ml arachidonic acid and 70%
ggregation with 10 mol/l ADP (28).
Optical aggregometry generally correlates well with clin-
cal outcomes (e.g., death, cardiovascular, and cerebrovas-
ular events), but there is often a lack of agreement with
ther measures of platelet function; for example, the Platelet
unction Analyzer-100 (PFA-100) (Dade Behring, Leider-
ach, Germany) (29). Besides, optical aggregometry has
everal other limitations, including the necessity to run the
nts
on of CV Events
Benefits of Aspirin Use With
Regard to End Points Comments
44% reduction in the risk of first MI
in the aspirin group; the greatest
effect of aspirin was seen in those
with the highest baseline CRP.
Data exclusively refer to primary
prevention in men. There is no
benefit of aspirin use in subjects
with lower baseline CRP.
Aspirin did not appear to have a
beneficial impact on the death or
incidence of MI and stroke.
Underpowered study, terminated
due to ethical issues.
Aspirin offered a 32% reduction in
nonfatal events.
Data exclusively refer to primary
prevention in men. Aspirin is not
as effective in preventing fatal
events as nonfatal. Combined
treatment with warfarin and
aspirin confer greater benefit,
although potential hemorrhagic
complications of the combined
regimen should be considered.
Acetylsalicylic acid significantly
reduced major CV events by 15%
(p  0.03) and MI by 36% (p 
0.002).
No difference in stroke incidence
between patients randomized to
acetylsalicylic acid or placebo.
Fatal bleeding did not differ
between groups. However,
nonfatal major and minor
bleedings were 1.8 times more
frequent among those treated
with aspirin.
Aspirin use significantly reduced CV
death rate (from 1.4% to 0.8%;
relative risk 0.56, 95% CI 0.31 to
0.99) and CV events (from 8.2%
to 6.3%; relative risk 0.77, 95% CI
0.62 to 0.95).
Severe bleeding complications
were 3 times more frequent in
the aspirin group, but the
benefit of aspirin therapy
significantly outweighed this
complication.
No significant effect of aspirin on the
risk of all MI or death from CV
causes. Women above 65 yrs of
age benefited most from aspirin
therapy. In this subgroup, the risk
of major CV events, ischemic
stroke, and MI was significantly
reduced.
First large trial assessing aspirin
efficacy in women.
Gastrointestinal bleeding requiring
transfusion was more frequent
in the aspirin group than in the
placebo group.
MI  myocardial infarction.V Eve
ventissay rapidly (usually within 1 to 3 h of blood collection) and
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Aspirin and CV Prevention May 13, 2008:1829–43dependence upon operator and interpreter experience. In
ddition, difficulties in reproducing and comparing results
btained in the same and different laboratories are fre-
uently reported (30). As an ex vivo test, optical aggregom-
try neglects to assess several important factors, such as the
nteractions between platelets, erythrocytes, neutrophils,
nd monocytes and also the high shear stress induced by
ascular injury.
To overcome some of these limitations, the PFA-100
evice (Dade Behring) was developed (31). This allows
easurement of the closure time of a microscopic aperture
n a membrane/cartridge coated with collagen/epinephrine
r collagen/ADP using whole blood anticoagulated with
odium citrate. The system simulates injured artery, high
hear stress conditions, and operates in the presence of
rythrocytes. Thus, platelet function is assessed by the time
aken to form a platelet plug occluding the aperture. Using
his test, aspirin resistance is generally defined as a closure
ime for a collagen/epinephrine cartridge of 164 s despite
egular aspirin intake.
What are the advantages of the PFA-100? The device is
imple to use and requires only a small volume of blood (800
l). The test is also quick and has good sensitivity and
eproducibility. Nonetheless, there are several limitations,
ncluding dependence upon plasma von Willebrand factor
nd hematocrit, the necessity to test blood samples within 3
o 4 h after blood collection, and expense: all factors that
estrict the widespread and practical applicability of this test.
Another point-of-care, easy-to-use, and rapid test for
efining aspirin resistance is the VerifyNow-Aspirin (the
ltegra Rapid Platelet Function Assay, Accumetrics Inc.,
an Diego, California), which is a turbidimetric-based
ptical detection system for measuring platelet-induced
ggregation (32). The VerifyNow-Aspirin assay correlates
ell with optical aggregometry, and uses an aspirin cartridge
ith fibrinogen-coated beads and a platelet activator (me-
allic cations, propyl gallate, arachidonic acid) to stimulate
he COX-1 pathway and to measure aspirin reaction units
32). The most important limitation of this test relates to its
iagnostic criteria, as these were set in comparison with
ptical aggregation in response to adrenaline, after only a
ingle 325-mg dose of aspirin.
Other laboratory measures of aspirin resistance are also
vailable. These include in vivo measurement of thrombox-
ne A2 pathway end products, such as serum thromboxane
2 (33) and urinary 11-dehydrothromboxane B2 (34).
either test specifically reflects platelet activity, but instead
ay reflect the contribution of monocytes/macrophages to
hromboxane A2 synthesis and also the COX-2 linked
athway of arachidonic acid, which is only partially blocked
y aspirin. In addition, ex vivo platelet activation during
lood sample collection, storage, and processing may also
nterfere with the results of these tests. Urinary 11-
ehydrothromboxane B2 concentrations are also highly
ependent on renal production of this metabolite, further
omplicating interpretation of this test. Nevertheless, as a telatively straightforward and inexpensive in vivo test that
an be performed on stored samples, the measurement of
rinary 11-dehydrothromboxane B2 is frequently used in
arge trials on aspirin resistance (34,35).
Measurement of platelet membrane-bound P-selectin
xpression by flow cytometry and the level of soluble
-selectin in plasma by enzyme-linked immunoadsorbent
ssay has also been employed in some studies of platelet
ctivation in disease states (22,36). However, the fact that
his molecule may be expressed on cells other than platelets
as resulted in conflicting data when this marker is used to
ssess aspirin efficacy (37,38).
ow Prevalent Is Aspirin Resistance?
any of the tests proposed to define the prevalence of
spirin resistance lack sensitivity, specificity, and reproduc-
bility. Indeed, a recent systematic review by Hovens et al.
39) reiterated this point, emphasizing that the prevalence
f aspirin resistance as defined by each test varied widely:
he lowest figure seen with optical aggregometry using arachi-
onic acid (6%; 95% CI 0% to 12%) and the highest prevalence
ith the PFA-100 analyzer (26%; 95% CI 21% to 31%).
Given the complexity of pathways of platelet activation
nd poor correlation between assays, some have advocated
sing a combination of criteria for aspirin resistance based
n multiple parameters. In a recent study by Sane et al. (40),
or example, aspirin resistance was considered to be present
f 4 of the following 5 criteria were met: collagen-induced
ggregation 70%; ADP-induced aggregation 60%;
hole-blood aggregation 18 Ohm; expression of glyco-
rotein IIa/IIIa 220 log mean fluorescence units; or
-selectin membrane receptor positivity 8%. Even with
his (very) strict definition, Sane et al. (40) reported that the
ncidence of aspirin resistance in heart failure patients was
hown to be 55%. In contrast, another study screening for
spirin resistance in patients receiving low-dose aspirin after
ransient ischemic attack or ischemic stroke found the
revalence of the aspirin resistance to be 17% using the
erifyNow-Aspirin assay, 22% by the PFA-100, 5% by
ptical aggregometry, and only 2% by the combination of
hese tests (31).
rospective Studies
lthough there are numerous studies of aspirin resistance,
nly 4 studies to date are of sufficiently large scale and
ell-designed, using doses of aspirin frequently prescribed in
linical practice (34,41–43) (Table 2). In each, the sample
ize was 100, and follow-up was for at least 1 year. Such
tudy design is important when assessing the relative prog-
ostic value of each test used to define aspirin resistance.
In these prospective studies, the lowest prevalence of
spirin resistance was defined using aggregometry (between
.2% and 8%) (41,42), while the PFA-100 analyzer yielded
he highest frequency of aspirin resistance (22.2%) (43). The
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May 13, 2008:1829–43 Aspirin and CV Preventionumber of major adverse events during the follow-up period
as relatively low in each study, and, thus, it became
nappropriate to draw firm conclusions on the significance
f aspirin resistance from these studies. Furthermore, each
as limited by failure to correct for confounding factors
particularly age and gender) and the failure to assess
dherence to aspirin by measurement of serum salicylate
evels. Certainly, it is possible and plausible that hyperten-
ion, diabetes, peripheral vascular disease, smoking, and
arious other confounding factors may contribute to aspirin
esistance, while also enhancing vascular risk (and thereby
ften necessitating aspirin therapy) in their own right. Such
otential confounders clearly need to be elucidated, as does
he effect of race and gender on the efficacy of aspirin
herapy.
Recently, researchers have even highlighted the dynamic
ature of aspirin resistance, the extent of which may vary, as
lood pressure and various biochemical markers do,
hroughout the day and with sickness and health (24,25,44).
onsequently, the value of a single point estimate measure
f aspirin resistance at baseline only is questionable, and
ertainly more advanced study designs are required.
ossible Causes of Aspirin Resistance
s the main antiplatelet mechanism of aspirin relates to
rreversible inhibition of COX-1 enzyme in mature platelets,
rospective Follow-Up Studies on Aspirin Resistance in Patients Tr
Table 2 Prospective Follow-Up Studies on Aspirin Resistance in
Reference Patients
Eikelboom et al. (34) 976 patients at high risk of cardiovascular
events treated with aspirin (75 to 325
mg/day). Aspirin resistance was
defined at baseline.
488 patients had MI, stroke, or
cardiovascular death during a follow-up
period (cases) and 488 patients had no
event (age- and gender-matched
control subjects). Mean age in the case
group, 67.3 yrs.
Pa
As
Gum et al. (41) 326 stable cardiovascular patients taking
aspirin 325 mg/day for at least 7 days.
Mean age 60.5 yrs.
M
Mueller et al. (42) 100 patients with intermittent
claudication after elective
percutaneous balloon angioplasty in
iliac-femoral arteries, treated with 100
mg/day aspirin. Mean age 62.5 yrs.
As
Pamukcu et al. (43) 234 patients with stable CAD treated with
100 to 300 mg/day aspirin. Mean age
57 yrs.
Th
DP  adenosine diphosphate; CAD  coronary artery disease; HOPE  Heart Outcomes Preventhe possible causes of aspirin resistance might be divided into tmain groups: those related to the COX-1 pathway of
hromboxane A2 production and those unrelated (Table 3).
In a series of small studies, an interesting hypothesis of
he PlA polymorphism (Leu33Pro, PlA1/A2) of the platelet
embrane glycoprotein IIIa gene as the main genetic
ackground of biological aspirin resistance has been sug-
ested (45–47). Carriers of the PlA2 allele, particularly in
he homozygous state, have been considered more resistant
o the antiplatelet action of aspirin and, thus, may require
reatment with alternative or additional agent(s).
Unfortunately, no prospective studies have investigated
he prognostic significance of glycoprotein IIIa gene poly-
orphisms, and only conflicting data are available (48,49).
lso, there is speculation that polymorphism of COX-1
ene, overexpression of COX-2 messenger ribonucleic acid
n platelets, and endothelial cells and polymorphism of
latelet glycoprotein Ia/IIa collagen-receptor gene might be
qually plausible causes for aspirin resistance (50). Clearly,
ore research is required to address these factors.
Based on a number of large trials and meta-analyses (10),
ow doses of aspirin (75 to 150 mg/day) are comparatively
afe and sufficient to inhibit platelet COX-1 and are as
ffective in preventing vascular events as higher aspirin doses
500 to 1,500 mg/day). In some patients, the failure to
uppress platelet COX-1 may be due to an inadequate
osage and reduced bioavailability of aspirin. In some cases,
With Low-Dose Aspirin
ients Treated With Low-Dose Aspirin
Study Description Results
enrolled in the HOPE trial
followed-up over 5 yrs.
d case-control design was
and baseline urinary
hydrothromboxane B2
were measured.
esistance was defined
vated urinary
hydrothromboxane B2.
Composite outcome of MI, stroke, or
cardiovascular death increased
with each increasing quartile of
11-dehydrothromboxane B2. Patients in
the upper quartile had a 2 times
greater risk of MI (OR 2.0; 95% CI 1.2
to 3.4; p  0.006) and a 3.5 times
greater risk of cardiovascular death (OR
3.5; 95% CI 1.7 to 7.4; p  0.001) than
those in the lower quartile.
llow-up period was 679  185
Aspirin resistance was defined
tical aggregometry as a mean
gation of 70% with 10 M
nd 20% with 0.5 mg/ml
idonic acid.
5.2% of patients were aspirin resistant at
baseline and had increased risk of
death, MI, or cerebrovascular accidents
compared with patients who were aspirin
sensitive (24% vs. 10%, hazard ratio
3.12, 95% CI 1.10 to 8.90; p  0.03).
esponse was monitored over a
of 12 months by corrected
blood aggregometry response
chidonic acid, ADP, and
en.
Reocclusion at the site of angioplasty
occurred in 8% of patients (in male
patients in whom aggregometry failed
to prove an inhibition of aggregation
upon ADP and collagen).
n follow-up period was 20.6 
onths. Aspirin resistance was
d by the Platelet Function
zer-100 as having a
al closure time of collagen/
phrine cartridge (186 s).
The baseline prevalence of aspirin
resistance was 22.2%. In the follow-up
period, major adverse cardiac events
occurred in 8 aspirin-resistant (15.4%)
and 20 aspirin-sensitive (11.0%)
patients (p  0.269). No relation was
found between aspirin resistance and
age, gender, hypertension, diabetes, or
hyperlipidemia.
luation; OR  odds ratio; other abbreviations as in Table 1.eated
Pat
tients
were
Neste
used
11-de
levels
pirin r
as ele
11-de
ean fo
days.
by op
aggre
ADP a
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epinehis may well relate to poor patient adherence (compliance),
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Aspirin and CV Prevention May 13, 2008:1829–43oncurrent administration of nonsteroidal anti-inflammatory
rugs (e.g., ibuprofen, indomethacin) and COX-2 inhibitors
which may compete with aspirin for platelet COX-1), or
ven a reduced absorption (or increased metabolism) of
spirin (24,51,52). Such concerns have been highlighted in
recent meta-analysis of 6 studies focusing either on
onadherence or premature discontinuation of aspirin in
ver 50,000 patients at high risk of coronary artery disease,
here a 3-fold increased risk of cardiac events (odds ratio
.14; 95% CI 1.75 to 5.61; p  0.0001) was related to
onadherence or the unjustified withdrawal of aspirin (53).
Nonetheless, poor compliance is not unique to aspirin
nd occurs to a certain extent with all prescribed medica-
ions. Various factors that increase nonadherence rates have
een identified and include polypharmacy (4 or more drugs,
ncluding aspirin and coadministration of other nonsteroidal
nti-inflammatory drugs), poor patient understanding of the
enefits of antiplatelet therapy, and side effects (54). Obvi-
usly, to overcome nonadherence to aspirin, it is quite
mportant to educate patients about the mechanism of
ction of this agent, as well as its difference from common
ardiovascular drugs (e.g., angiotensin-converting enzyme
ACE] inhibitors, beta-blockers, calcium antagonists, an-
idiabetic drugs, and statins), which demonstrate their effect
ithin relatively short periods of time, and in clinical
ractice, their effects can be easily quantified (e.g., blood
ressure, heart rate, glucose, and lipid levels). To further
xplore the role of nonadherence and its relevance to the
tudies of aspirin resistance, Schwartz et al. (55) tested
latelet function by arachidonic acid-induced light aggre-
ometry in patients with a prior MI. Measurements were
aken while patients were receiving their usual daily aspirin,
fter stopping aspirin for 7 days, and then 2 h after ingestion
f aspirin, 325 mg; at the first time point, laboratory
onresponsiveness to aspirin was observed in 17 patients
9%), whereas at the third time point only in 1 patient
Possible Causes of Aspirin Resistance
Table 3 Possible Causes of Aspirin Resistan
COX-1–Related Causes
Poor patient compliance
Failure to prescribe aspirin properly (premature
discontinuation of therapy)
Concurrent administration of nonsteroidal
anti-inflammatory drugs competing with
aspirin for binding with COX-1
Reduced absorption of active acetylsalicylic acid
due to inadequately low dose of aspirin,
intake of proton pump inhibitors, advanced
age and weight
Increased platelet turnover in response to stress
conditions
Polymorphisms of COX-1 gene
ADP  adensine diphosphate; COX  cyclooxygenase.0.5%). sAge, weight, and intake of proton pump inhibitors may
lso reduce the bioavailability of low-dose aspirin, mainly
ue to increased inactivation of acetylsalicylic acid by
astrointestinal mucosal esterases and reduced absorption of
ctive acetylsalicylic acid (24). Although low-dose aspirin
ay potentially be a cause of apparent aspirin resistance
hrough reduced absorption, the use of higher doses of
spirin seems unjustifiable and is outweighed by an in-
reased risk of gastrointestinal bleeding (56). However, in
onditions accompanied by increased platelet turnover (e.g.,
cute coronary syndromes, coronary artery bypass grafting
nd other surgical procedures, acute or chronic infection,
nflammation), a temporary increase of aspirin dose seems
easonable, albeit unproven. Under these circumstances,
ow-dose aspirin, given its short half-life (15 to 20 min), is
nable to inhibit COX-1 in platelets rapidly released into
he circulation (57– 60). However, although COX-1-
ependent mechanisms are suggested to be responsible for
spirin resistance in these conditions, it is more likely that
ore complex pathways and proinflammatory/thrombogenic
olecules are also involved. Circumstantial evidence for this
laim is available as aspirin resistance (as defined by PFA-100)
s twice as common in acute coronary syndromes complicated
y pneumonia compared with those cases without infectious
omplications (90% vs. 46%) (60). In addition, there appears
o be an independent association between CRP and aspirin
esistance in these patients.
Thus, in conditions that are associated with both infec-
ion and inflammation, nonplatelet sources of thromboxane
2 production (e.g., monocytes, macrophages, endothelial
ells) and up-regulation of the COX-2 enzyme coupled
ith increased levels of F2-isoprostanes may lead to uncon-
rolled thromboxane synthesis. Such COX-1-independent
echanisms are especially relevant to patients with diabetes
ellitus (61–63), hyperlipidemia (64), smoking (65), and
eart failure (66–68), all of which are associated with
ugmented lipid peroxidation of arachidonic acid and con-
COX-1–Nonrelated Causes
gulation of COX-2 pathway of thromboxane A2 production
platelets, monocytes, macrophages and endothelial cells
ased production of prostaglandin F2-like compounds by
id peroxidation of arachidonic acid
itions associated with activation of platelets by collagen
/IIa receptors, von Willebrand factor, ADP receptors,
rombin, serotonin, catecholamines, and shear stress
orphisms of glycoprotein IIIa (PlA1/A2), glycoprotein Ia/IIa
llagen receptor genesce
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ts assessment.
Studies defining the causes of aspirin resistance suggest
hat the mechanistic approach to this phenomenon have
elied largely on COX-1 pathway studies, and the use of
more specific” laboratory tests employing arachidonic acid-
nduced platelet activation and aggregation is often far from
eing pathophysiologically justifiable, pragmatic, or practi-
al (69,70). To predict the risk of atherothrombotic events
n patients on aspirin, a comprehensive approach to measure
Figure 2 Role of COX-1–Related and Nonrelated Mechanisms o
Figure illustration by Rob Flewell. COX  cyclooxygenase; CRP  C-reactive proteinesidual platelet reactivity caused by the arachidonic acid mathway (and perhaps, multiple pathways), which are
nonblocked” by aspirin, seems more important, albeit
ignificantly less straightforward and poorly explored (71)
Fig. 2).
spirin Resistance in Cardiovascular Disorders
eart failure. Many of the complications associated with
eart failure are thrombus related. Given the high mortality
nd morbidity associated with heart failure, aspirin resistance
irin Resistance in Several Clinical Conditionsf Asp
.ay play a role. To date, only 1 study has found a high
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Aspirin and CV Prevention May 13, 2008:1829–43revalence of aspirin resistance in heart failure. In this study,
ane et al. (40) examined 88 patients with congestive heart
ailure treated with aspirin (325 mg/day) for more than 1
onth and found aspirin resistance to be present in as much as
5% of patients.
Is this clinically significant? Indeed, there is conflicting
vidence regarding the benefits of aspirin in reducing the
igh incidence of vascular events in patients with chronic
eart failure (72), and aspirin may possibly attenuate the
fficacy of ACE inhibitors in heart failure patients (73). In
large study of 24,012 patients age 65 years or older with
eart failure secondary to coronary artery disease, those
aking aspirin (54%) only had modestly lower risk of death
risk ratio 0.94; 95% CI 0.90 to 0.99) and were relatively
ree of a negative interaction with ACE inhibitors (74).
ther observational studies (e.g., patients with ischemic
ardiomyopathy, age over 75 years) found no difference in
ll-cause mortality and hospitalization within 1 year of
ndex hospitalization regardless of aspirin usage (75).
To date, the efficacy of aspirin in heart failure has been
ssessed in 3 controlled prospective trials. In the WASH
Warfarin/Aspirin Study in Heart failure) trial, patients
ith heart failure were recruited and randomized to placebo,
spirin 300 mg/day, or warfarin. Within the follow-up
eriod (27  1 months), patients taking aspirin had more
ospitalizations due to heart failure (p  0.044). However,
here was no difference in primary outcomes of the study
death, nonfatal MI, or stroke) between the 3 study arms
76). In a larger trial, the WATCH (Warfarin and Anti-
latelet Therapy in Chronic Heart failure) trial, patients
ere randomized to aspirin (162 mg), clopidogrel, or
arfarin (77). Unfortunately, this trial was underpowered
nd terminated prematurely due to poor patient recruit-
ent. Again, there was no detectable difference in primary
utcome between 3 arms, but hospitalization rate in the
spirin arm was significantly higher (22.2% vs. 16.1% and
8.3% for aspirin, warfarin, and clopidogrel, respectively;
 0.01). Finally, the HELAS (Heart Failure Long-term
ntithrombotic Study) was initially aimed at recruiting
,000 patients with chronic heart failure of New York Heart
ssociation functional class II to IV (78). Patients were
andomized to aspirin 325 mg daily, warfarin, or placebo
nd followed for 2 years to determine the rate of thrombo-
mbolic, hemorrhagic, and lethal events. Again, this trial
as terminated prematurely because of recruitment difficul-
ies, and only 197 patients with left ventricular ejection
raction 35% were enrolled, with no significant difference
hown in the incidence of MI, hospitalization, heart failure
ecompensation, death, and hemorrhage rate between the
roups (79).
Such data have led to the conclusion that aspirin therapy may
ossibly attenuate the efficacy of ACE inhibitors and, therefore,
xplain the increased hospitalization rate in heart failure patients
aking aspirin in these trials (73). Given the paucity of evidence for
se of aspirin in heart failure and the apparent high rate of aspirin
esistance, further prospective trials are required in this setting b72). The WARCEF (Warfarin versus Aspirin in patients with
educed Cardiac Ejection Fraction) trial, a large multinational
andomized trial with a target enrollment of 2,860 patients, is
ngoing and will randomize patients with systolic heart failure to
spirin or warfarin (80).
iabetes mellitus. As is the case with other diseases that
ontribute to cardiovascular risk, many advocate the use of aspirin
n patients with diabetes mellitus, even in the absence of strong
vidence from major prospective clinical trials. One prime example
s a subgroup analysis of patients with type 2 diabetes mellitus
rom the PPP (Primary Prevention Project) trial, one-half of
hom were taking aspirin (81). This drug failed to reduce
lobal cardiovascular events in diabetic patients, but did
ppear to confer a significant reduction in stroke events.
Despite the lack of prospective studies to support the use
f low-dose aspirin in diabetic patients, this agent is
onsidered a cornerstone of primary and secondary preven-
ion of thrombotic cardiovascular, cerebral, and peripheral
rterial events in both type 1 and type 2 diabetes mellitus
82–85). Much of the evidence for this argument stems
irectly from the Antiplatelet Trialists’ Collaboration meta-
nalysis (10), which found a significant reduction in isch-
mic vascular events by use of aspirin in a subgroup of
atients with diabetes mellitus.
There are only limited direct data on the prevalence of
spirin resistance in diabetes mellitus. Given the complex
athophysiology of diabetes mellitus and the frequent asso-
iation with other disorders (e.g., hyperlipidemia, hypergly-
emia, hypertension, endothelial dysfunction, chronic in-
ammation, accelerated atherogenesis, hypercoagulable
tate, micro- and macro-vasculopathy, and so on) all of
hich may significantly up-regulate COX-1–independent
athways of platelet activation and aggregation, it is con-
idered that the prevalence of aspirin resistance is likely to
e substantial (86,87). In a cohort of 488 patients with
spirin resistance in the HOPE (Heart Outcomes Preven-
ion Evaluation) trial, 32.6% had diabetes mellitus (34). In
group of type 2 diabetic patients treated with aspirin 100
g daily, the prevalence of aspirin resistance was estimated
t 21.5% using the PFA-100 analyzer with collagen/
pinephrine cartridges (88). However, the authors did not
nd any association between aspirin resistance and cardio-
ascular events after 1-year follow-up, nor any association
etween aspirin resistance and confounding factors (hyper-
ipidemia, hyperglycemia, hypertension, obesity, or smok-
ng). This study was small, and further prospective long-
erm studies are required to assess the real clinical
ignificance of aspirin resistance in diabetes.
ypertension. For secondary prevention, the benefit of
ntiplatelet therapy with aspirin in subjects with hyperten-
ion is well established and supported by strong trial data
89). For primary prevention, however, the evidence is less
obust. In the large HOT (Hypertension Optimal Treat-
ent) trial, the efficacy of aspirin in reducing major cardio-
ascular events (in particular, MI, not stroke) was evident,
ut aspirin increased the risk of major and minor nonfatal
b
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May 13, 2008:1829–43 Aspirin and CV Preventionleedings, and there was no major effect on mortality (14).
erhaps this may, in part, relate to aspirin resistance, as a
ignificant proportion of patients (45% to 63.5%) with this
henomenon do, in fact, have hypertension (34,45). None-
heless, little is known about aspirin response and its
rognostic value in patients with arterial hypertension.
As appears to be the case with heart failure and with
iabetes mellitus, a number of factors may contribute to
ltered platelet reactivity and lead to relatively high fre-
uency of aspirin resistance among subjects with hyperten-
ion. As already discussed, this presumably occurs predom-
nantly through activation of COX-1–independent mechanisms.
n the case of hypertension, this is likely not only related to
ltered production of thromboxane A2, but also, given the
leiotropic function of aspirin, may be related to the
ctivation of nitric oxide (NO) synthase and an increase in
O production by platelets (90). The increased NO may
hen counteract various prothrombotic and hypertensive
actors, and, thereby, may be implicated in the clinical
fficacy of aspirin.
In a recent study, Feher et al. (91) investigated the
resence of hypertension and aspirin resistance among
atients with cardiovascular and cerebrovascular disease who
ere taking aspirin 100 to 325 mg daily. They found a
ignificantly higher prevalence of hypertension among
spirin-sensitive patients compared with that seen in
spirin-resistant patients (80% vs. 62%; p  0.05). How-
ver, there was also a significantly higher rate of beta-
locker and ACE inhibitor usage among aspirin-sensitive
atients; these drugs may exert an additive antiplatelet
ction when combined with aspirin. Oddly, the use of
tatins was shown to be an independent predictor of aspirin
esistance.
heumatic diseases. Autoimmune, inflammatory, and
hrombotic reactions may be enhanced by various rheumatic
iseases, and—in conjunction with classic cardiovascular
isk factors—may accelerate the course of atherosclerosis,
eading to premature manifestation(s) of cardiovascular
isease (92–94). In this context, both the anti-inflammatory
nd the antiplatelet properties of aspirin may be crucial for
rimary and secondary prevention.
In a study of almost 9,000 cases of a first-time MI among
atients registered on the British General Practice Research
atabase, the highest risk of MI was found in patients with
heumatoid arthritis or systemic lupus erythematosus (ad-
usted odds ratio 3.68; 95% CI 2.36 to 5.74) and in those
ollowing cessation of nonsteroidal anti-inflammatory drugs
fter long-term use (adjusted odds ratio 2.60, 95% CI 1.84
o 3.68) (95). In a post-mortem study of patients with
heumatoid arthritis, atherosclerosis was less prevalent
mong those subjects with a prolonged course of arthritis
more than 8 years) and regular aspirin use (96). An inverse
elationship was found between the prevalence of symptom-
tic atherosclerosis and duration of aspirin intake.
Such findings should be considered carefully with evi-
ence from a number of small studies suggesting that the Hfficacy of antiplatelet therapy with aspirin may be dimin-
shed by persistent inflammation (e.g., from rheumatic
isease) and concurrent use of other nonsteroidal anti-
nflammatory drugs, and may even be negated by the
otential risk of major gastrointestinal hemorrhage (97,98).
arge-scale, prospective studies investigating the relation-
hip between low-dose aspirin usage, aspirin resistance,
nflammation, and cardiovascular risk are awaited.
herapeutic Opportunities for Aspirin Resistance
spirin resistance is a multifactorial phenomenon, and
reatment should, therefore, be directed to a number of
OX-1–dependent and –independent factors, some of
hich may be modifiable (e.g., patient compliance, aspirin
osage, drug–drug interactions, and increased platelet turn-
ver). Adequate treatment of confounding clinical condi-
ions such as smoking, hyperlipidemia, hyperglycemia, hy-
ertension, heart failure, infection, and inflammation
ay further increase efficacy of antiplatelet treatment with
spirin.
In some patients, an increased dose of administered
spirin may prove useful to overcome resistance (e.g., acute
oronary syndromes, infections, inflammation, and so on).
his approach is unjustifiable and even unsafe in diabetes,
hronic heart failure, and rheumatic heart disease. In addi-
ion, the available evidence does not consider aspirin doses
igher than 81 mg as either effective or safe (56).
The most logical and promising approach, therefore,
eems to be the addition of other antiplatelet or antithrom-
otic drugs to aspirin therapy rather than replacement of
spirin in clinical conditions where aspirin resistance is
nticipated. In several studies, platelet sensitivity to ADP
nd levels of this agonist in patients with aspirin resistance
ere shown to be significantly increased (99,100). In addi-
ion, those patients with the least sensitivity to the effect of
spirin on the arachidonic acid pathway appeared to be
ighly sensitive to the P2Y12 platelet ADP receptor antag-
nist clopidogrel (101). Such data suggest the potential
or dual antiplatelet therapy, and, consequently, this
pproach has been addressed by several large randomized
rials (Table 4) (102–108).
Dual antiplatelet therapy with clopidogrel and aspirin
emonstrates statistically significant additive benefit (in
erms of primary end points and bleeding rate) over
spirin monotherapy in various clinical trials (COMMIT
ClOpidogrel and Metoprolol in Myocardial Infarction
rial], CURE [Clopidogrel in Unstable angina to pre-
ent Recurrent Events], PCI-CURE [substudy of
URE], CREDO [Clopidogrel for the Reduction of
vents During Observation]) (Table 4) (102–105).
In two large trials, the CHARISMA (Clopidogrel for
igh Atherothrombotic Risk and Ischemic Stabilization,
anagement, and Avoidance) trial and the MATCH
Management of ATherothrombosis with Clopidogrel in
igh-risk patients) trial, with 15,603 and 7,599 high-risk
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Aspirin and CV Prevention May 13, 2008:1829–43ardiovascular and cerebrovascular patients, respectively,
here was no difference in the primary end points between
he dual and monotherapy arms of the trials. Importantly, of
he broad range of high-risk atherothrombosis patients
nrolled in the CHARISMA trial, a subgroup of 9,478
andomized Prospective Trials of Dual Antiplatelet Therapy With C
Table 4 Randomized Prospective Trials of Dual Antiplatelet The
Trial Patients
The COMMIT trial (102) 45,852 patients with suspected acute MI. Clop
1
p
The CURE trial (103) 12,562 patients with non–ST-segment
elevation acute coronary syndromes
followed up to 1 yr (mean 9 months).
Clop
d
d
d
p
The PCI-CURE trial
(CURE substudy)
(104)
2,658 patients with non–ST-segment
elevation ACS undergoing PCI.
Pre-
o
a
in
m
g
a
t
T
r
p
m
The CREDO trial (105) 2,116 patients who were either
scheduled to undergo PCI or were at
high likelihood of undergoing PCI.
Clop
d
d
a
a
t
c
a
a
The CARESS trial (106) 107 patients with symptomatic carotid
stenosis with asymptomatic
microembolic signals detected by
transcranial Doppler ultrasound.
Clop
d
d
m
p
The CHARISMA trial
(107)
15,603 patients with a history of
symptomatic CAD, cerebrovascular
disease, or peripheral arterial disease
or at high cardiovascular risk.
Clop
a
v
The MATCH trial (108) 7,599 patients with recent ischemic
stroke or transient ischemic attack
and at least 1 additional vascular risk
factor.
Asp
c
v
c
CS  acute coronary syndromes; ADP  adenosine diphosphate; CAD  coronary artery disease
lopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance;
vents During Observation; CURE  Clopidogrel in Unstable angina to prevent Recurrent Events; M
oronary intervention; other abbreviations as in Table 1.atients with prior MI, stroke, and symptomatic peripheral 0rterial disease did appear to benefit from dual antiplatelet
herapy (109). In this subgroup analysis, the composite end
oint of cardiovascular death, MI, and stroke was lower in
he clopidogrel plus aspirin arm compared with the placebo
lus aspirin arm (7.3% vs. 8.8%; hazard ratio 0.83, 95% CI
grel and Aspirin
With Clopidogrel and Aspirin
telet Treatment Results
l 75 mg/day plus
/day aspirin versus
plus aspirin.
In the follow-up period (up to 4 weeks), in the
clopidogrel group there was a 9% reduction in the
composite of death, reinfarction, or stroke (95% CI
3% to 14%; p  0.002) and a 7% reduction in all-
cause mortality (95% CI 1% to 13%; p  0.03).
l (300-mg loading
llowed by 75 mg/
s 75 to 325 mg/
irin versus placebo
pirin.
Dual therapy reduced by 20% the relative risk of
cardiovascular death, nonfatal MI, and stroke (p 
0.001). Although the incidence of major bleeding
was comparatively high in the clopidogrel-treated
group, there was no difference in the incidence of
life-threatening bleeding and hemorrhagic stroke.
ent with clopidogrel
bo plus aspirin for
n of 10 days before
tion. After PCI,
an 80% in both
received ADP
ist (clopidogrel or
ine) for 4 weeks.
tients continued to
clopidogrel or
for an average of 8
.
Dual therapy (clopidogrel-aspirin) reduced by 30% the
relative risk of cardiovascular death, MI, and urgent
target vessel revascularization within a month after
PCI (p  0.03). In the follow-up period, there was no
significant difference in major bleedings between
the groups.
l (300-mg loading
llowed by 75 mg/
s 325 mg/day
versus placebo plus
From 29th day
12 months:
grel 75 mg/day plus
or placebo plus
In the follow-up period, dual antiplatelet therapy
reduced by 26.9% the relative risk of death, MI, and
stroke (95% CI 3.9% to 44.4%, p  0.02).
l (300-mg loading
llowed by 75 mg/
7 days) plus 75
aspirin versus
plus aspirin.
On day 7 microembolic signals were detected in 43.8%
of patients in the dual antiplatelet therapy group
and in 72.7% in the monotherapy with aspirin group
(relative risk reduction 39.8%, 95% CI 13.8% to
58.0%; p  0.0046).
l 75 mg/day plus
75 to 162 mg/day
placebo plus aspirin.
In the 28-month follow-up period, there was no
difference in the rate of cardiovascular death, MI,
and stroke between the groups (relative risk 0.93;
95% CI 0.83 to 1.05; p  0.22). In the clopidogrel
plus aspirin group, hospitalization rate for ischemic
events was 16.7% versus 17.9% in the aspirin
group (relative risk 0.92, 95% CI 0.86 to 0.995; p 
0.04). The rate of severe bleeding was 1.7% and
1.3%, correspondingly (relative risk 1.25, 95% CI
0.97% to 1.61%; p  0.09).
mg/day plus
grel 75 mg/day
placebo plus
grel 75 mg/day.
After 18 months, dual antiplatelet treatment was
associated with 1% nonsignificant absolute
reduction of major ischemic events and a significant
1.3% absolute risk increase of the life-threatening
bleeding (95% CI 0.6 to 1.9). The rates of fatal
bleeding and all-cause mortality were not different
between the groups.
S  Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis; CHARISMA
IT  Clopidogrel and Metoprolol in Myocardial Infarction; CREDO  Clopidogrel for the Reduction of
 Management of ATherothrombosis with Clopidogrel in High-risk patients; PCI  percutaneouslopido
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May 13, 2008:1829–43 Aspirin and CV Preventionoints, hospitalization rate over the mean follow-up period
f 27.6 months was significantly lower in the clopidogrel
lus aspirin arm (11.4% vs. 13.2%; hazard ratio 0.86, 95%
I 0.76 to 0.96; p  0.008), and there was no difference in
he rate of severe bleeding. This subgroup analysis of the
HARISMA trial stressed the importance of identifying
elected patients who would benefit from dual antiplatelet
herapy.
This notion is further supported by recent analysis of
xcess cardiovascular death rate in the CHARISMA trial of
symptomatic patients treated with dual antiplatelet therapy
110), and by results of 2 small studies, the PLUTO-CHF
PLavix Use for Treatment Of Congestive Heart Failure)
111) and prospective follow-up study of aspirin resistance
y Pamukcu et al. (43). In the latter small studies, patients
eeting criteria of laboratory aspirin resistance were ran-
omly selected to receive clopidogrel plus aspirin therapy. In
he PLUTO-CHF study, dual aspirin-clopidogrel therapy
ver 1 month resulted in significant changes in a number of
latelet activation laboratory parameters in a small cohort
n  25) of heart failure patients. Pamukcu et al. (43)
eported 28 patients with coronary artery disease who were
ollowed-up over a 6- to 12-month period, and those who
eceived additional clopidogrel therapy over 12 months had
ess cardiovascular events than those who did not use or
topped clopidogrel at 6 months.
Although dual aspirin-clopidogrel therapy may seem to
e the most beneficial therapeutic approach to aspirin
esistance, a rapidly increasing number of publications
ecognize the existence of “clopidogrel resistance” (25,111–
14) and even “dual aspirin-clopidogrel resistance” (115).
hese observations necessitate further search for new, more
otent antiplatelet agents suitable for long-term cardiovas-
ular prevention. Among these agents are thienopyridine
ompound, prasugrel (CS-747, LY 640315), which provides
0 times more potency, rapid and sustained antiplatelet
ffect, when compared with clopidogrel (111,116), and an
ral reversible inhibitor of P2Y12 receptor AZD6140 (117).
Another approach to enhance antiplatelet effect of aspirin
s an addition of dipyridamole. Combination therapy with
spirin and dipyridamole is used in the setting of secondary
revention after stroke. The evidence for this comes from
he ESPS (European Stroke Prevention Study)-2 trial with
treatment arms (50 mg/day aspirin, 400 mg/day dipyrid-
mole, dual therapy and placebo) (118). This trial showed
2% relative risk reduction of major vascular events in
atients with dual aspirin-dipyridamole therapy compared
ith that seen with aspirin alone, but no significant effect on
ascular death rate. Additionally, the ESPRIT (European/
ustralasian Stroke Prevention in Reversible Ischaemia
rial) study compared efficiency of aspirin (30 to 325
g/day) with or without dipyridamole (400 mg/day) in
atients with transient ischemic attack or minor stroke
119). The composite of vascular death, nonfatal stroke,
onfatal MI, and major bleeding was evaluated over a mean
ollow-up period of 3.5 years; superiority of clinical efficacy rf combined therapy was demonstrated (absolute annual
isk reduction 1.0%, 95% CI 0.1 to 1.8) (119). Nevertheless,
t is noteworthy that meta-analysis by Antithrombotic
rialists’ Collaboration showed no difference in efficacy
etween aspirin plus dipyridamole and aspirin alone in high
ascular risk patients (10). These results were reiterated by a
ecent systematic review of 29 trials with more than 23,000
atients with arterial vascular disease (120). No evidence
as found that dipyridamole alone or in combination with
spirin significantly reduced the risk of vascular death,
lthough it was efficacious in secondary prevention of
erebrovascular ischemic events.
In patients undergoing percutaneous coronary angio-
lasty, significant improvement of clinical efficacy of aspirin
lone or in combination with clopidogrel may be achieved
y addition of cilostazol, a phosphodiesterase type 3 inhib-
tor with potent antiplatelet, vasodilative, antiproliferative,
ndothelial function, and lipid profile improving effects
121,122). In the CREST (Cilostazol for RESTenosis)
rial, addition of cilostazol to aspirin and clopidogrel therapy
educed the rate of restenosis by 36% after successful
are-metal stenting (123). It proved to be efficient in
atients with peripheral arterial disease as well (124).
Whether addition of new inhibitors of P2Y12 receptor,
ipyridamole, or cilostazol to aspirin is an effective inter-
ention for subjects with aspirin resistance remains to be
lucidated in future studies.
onclusions
espite the emergence of “aspirin resistance” as a clinical
henomenon, aspirin still remains the most commonly
rescribed drug for prevention of atherothrombotic events.
his is due not only to its potent inhibition of the
hromboxane A2 pathway, which is undoubtedly crucial for
latelet activation and aggregation, but also because of a
umber of pleiotropic effects (suppression of acute phase
eactants and subclinical inflammation, stimulation of NO
ynthesis, immunomodulatory effect on activated macro-
hages and lymphocytes, and so on) (125–127). Further-
ore, aspirin has proved complementary to—and seems to
otentiate—the effects of other antiplatelet agents (such as
lopidogrel, dipyridamole, cilostazol) in the case of com-
ined therapy. In addition, aspirin seems to be generally
ell tolerated by most patients, and relatively few have
ontraindications to this drug or develop major bleeding.
uch characteristics mean that aspirin is likely to remain the
ornerstone of antiplatelet therapy for long-term cardiovas-
ular prevention.
As discussed in this review, numerous modifiable and
onmodifiable factors may interfere with aspirin therapy,
reventing its targeted action on the thromboxane A2
athway, thereby attenuating the effect of this drug on
latelet activation and aggregation and limiting its role in
ardiovascular prevention. The terms “biochemical or labo-
atory” and “clinical” aspirin resistance have been suggested
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Aspirin and CV Prevention May 13, 2008:1829–43o better characterize those patients who do not benefit from
ong-term aspirin use. Despite this, relatively few well-
esigned prospective studies have been conducted thus far,
ielding some evidence that is suggestive of a possible link
etween the inefficient inhibition of thromboxane A2 path-
ay and adverse cardiovascular events over long-term
ollow-up. Unfortunately, these studies lack a standardized
efinition of aspirin resistance based on validated and widely
vailable methods of platelet function assessment. As a
atter of fact, studies comparing main laboratory tests for
etection of aspirin resistance (optical and whole blood
ggregometry, PFA-100, VerifyNow-Aspirin, level of uri-
ary 11-dehydro-thromboxane B2) found poor agreement
etween these tests (128) and left unresolved the issue of
tility of these tests for routine measurements of aspirin
esistance.
The available evidence does not adequately address the
ssue of dynamic changes in platelet function and whether
spirin resistance persists over a period of time when
ultiple intrinsic and extrinsic factors may exert their effect
n platelet function in multiple directions. To address this
ssue, design of future prospective studies should include
aseline and follow-up measurements of platelet function in
atients with accurately monitored compliance to long-term
spirin use.
Actually, future studies of aspirin resistance should also
onsider complex interactions between age, gender, and
thnicity, as it is becoming more obvious that these factors
ay have an impact on the extent of inhibition of COX-1
athway by aspirin (129–131). Finally, the issue of aspirin
esistance should be considered separately for those who
ay not benefit from aspirin due to COX-1–related and
nonrelated genetic factors (131). Until further studies are
vailable to investigate aspirin resistance in more depth, a
alanced approach is required when assessing patients for
ntiplatelet therapy. Certainly, comorbidities that may en-
ance aspirin resistance (e.g., diabetes mellitus, hyperten-
ion, heart failure, inflammatory disorders, and so on)
hould be actively sought, as this may aid the practicing
linician in deciding between monotherapy with aspirin or
oprescription with other more potent antiplatelet drugs.
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